BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Soliris (Eculizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Soliris (Eculizumab)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06724809-886@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20261207
DTEND;VALUE=DATE:20261208
SUMMARY:Soliris (Eculizumab): Phase 3 readout est. (NCT06724809)
DESCRIPTION:Soliris (Eculizumab)\, phase 3.\nStudy: Efficacy\, Safety\, PK\
 , PD\, and ADA of Eculizumab in Chinese Adults With NMOSD\nEstimated prima
 ry completion: 7 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/eculizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06724809
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420296-886@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Soliris (Eculizumab): Phase 3 readout est. (NCT07420296)
DESCRIPTION:Soliris (Eculizumab)\, phase 3.\nStudy: Modified Zipper Therapy
  for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder\nEstimated p
 rimary completion: 31 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/eculizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07420296
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449001-886@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Soliris (Eculizumab): Phase 3 readout est. (NCT06449001)
DESCRIPTION:Soliris (Eculizumab)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study of Danicopan as Add-on Treatment to Ravulizumab or Ec
 ulizumab in Pediatric Participants With PNH Who Have Clinically Significan
 t Extravascular Hemolysis\nEstimated primary completion: 28 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/eculizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06449001
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410039-886@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Soliris (Eculizumab): Phase 4 readout est. (NCT07410039)
DESCRIPTION:Soliris (Eculizumab)\, phase 4.\nStudy: Therapy in the Acute Ph
 ase of NMOSD: A Multicenter Prospective Real-World Study\nEstimated primar
 y completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/eculizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07410039
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05731050-886@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Soliris (Eculizumab): Phase 2 readout est. (NCT05731050)
DESCRIPTION:Soliris (Eculizumab)\, phase 2\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study of NM8074 in Soliris-Treated Patients With Paroxysmal
  Nocturnal Hemoglobinuria (PNH)\nEstimated primary completion: September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/eculizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05731050
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707687-886@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Soliris (Eculizumab): Phase 2 readout est. (NCT07707687)
DESCRIPTION:Soliris (Eculizumab)\, phase 2\, Thrombotic Microangiopathy.\nS
 tudy: Safety and Efficacy of Eculizumab in High-risk TA-TMA\nEstimated pri
 mary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/eculizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07707687
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05646563-886@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Soliris (Eculizumab): Phase 2 readout est. (NCT05646563)
DESCRIPTION:Soliris (Eculizumab)\, phase 2\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study of NM8074 in Adult PNH Patients With Inadequate Respo
 nse to Soliris\nEstimated primary completion: July 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/eculizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05646563
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010302-886@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Soliris (Eculizumab): Phase 4 readout est. (NCT07010302)
DESCRIPTION:Soliris (Eculizumab)\, phase 4.\nStudy: Rituximab Versus Ravuli
 zumab\, Inebilizumab\, Satralizumab\, and Eculizumab in NMOSD\nEstimated p
 rimary completion: January 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/eculizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07010302
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
